Meeting
2023 ASCO Annual Meeting
Detection of homologous recombination deficiency (HRD) using a novel genomic and epigenomic liquid biopsy assay in patients with breast cancer.
Authors
Catalin Barbacioru
Guardant Health, Redwood City, CA
Catalin Barbacioru , Jennifer Yen , Denis Tolkunov , Pegah Safabakhsh , Hao Wang , Andrew Gross , Brooke Overstreet , Colby Jenkins , Leylah Drusbosky , Lesli Ann Kiedrowski , Craig Eagle , Han-Yu Chuang
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Local/Regional/Adjuvant
Track
Breast Cancer
Sub Track
Adjuvant Therapy
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 556)
DOI
10.1200/JCO.2023.41.16_suppl.556
Abstract #
556
Poster Bd #
386
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Prevalence of germline mutations and homologous recombination deficiency (HRD) in a real-world biliary tract cancer (BTC) cohort.
First Author: Robin Kate Kelley
Poster
2020 ASCO Virtual Scientific Program
Comparison of genomic instability test scores used for predicting PARP activity in ovarian cancer.
First Author: Kirsten M Timms
Poster
2023 ASCO Annual Meeting
HRD signature and HRD genomic landscape of tumors from 896 patients with early-stage breast cancer (BC).
First Author: June Evelyn Jeon
Poster
2023 ASCO Annual Meeting
A four-tier classification system for studying homologous recombination repair gene reversion mutations as a mechanism of resistance to PARP inhibitors and platinum chemotherapy.
First Author: Qiuxiang Ou